EGFR and cancer: Activation of bypass signaling (via amplification or mutations of HER2, FGFR1, MET, and PDGFR) or downstream signaling (via mutations of NRAS, BRAF, PIK3CA, or deletion of PTEN) in cancer cells has been shown to contribute to resistance to anti-EGFR antibodies [21].